SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
50678Ongoing saga (Spectral Medical inc.) of Targeted therapy for septic shock.. SiSultan-1/18/2019
50677From Scientific American January 2019 issue “Clinical Trials Have the Best MedicBulbaMan-1/18/2019
50676Got it. Thanks Jim!atticus4paws-1/18/2019
50675<If anyone knows (so my lazy self doesn't have to look it up) what intereBiotech Jim-1/18/2019
50674Just reading through LGND's 2018Q3 10-Q to get a better feel for how the stoatticus4paws-1/18/2019
50673Rhonda Patrick had a recent article about APOE4 carriers not being able to get nGeorge Statham-1/16/2019
50672Or it could be just normal volatility ramp up to the Jun expiration. We canatticus4paws-1/16/2019
50671With the March expiration open, it appears, from the ROC's (ret. on capital)atticus4paws-1/16/2019
50670AEZS is interesting when you crunch the #'s given the mkt cap, today's Eoldirtybastard-1/16/2019
50669>>The primary is now FVC Actually it's been FVC since the trial was fBiomaven-1/15/2019
50668Mortality in DMD is about evenly divided between respiratory and cardiac. All Biomaven-1/15/2019
50667A legal dispute between Edwards Life Sciences (EW) and Boston Scientific (BSX) hOldAIMGuy-1/15/2019
50666DMD is open label and Neff seemed to highlight the coming data in the last CC soDaveAu-1/14/2019
50665Selling covered calls is indeed a good hedge, as long as: 1. The expiration of Art Bechhoefer-1/14/2019
50664Less worried about June expiration not getting the job done. It occurred to me tuck11/14/2019
50663AZN - Recent changes in management ranks and shifting strategy. bloomberg.comsemi_infinite -1/14/2019
50662If I am correct, Tuck is looking to sell FGEN calls contract, as *hedge*!Miljenko Zuanic-1/14/2019
50661Seems to me you'd be better off avoiding the purchase of call options (generArt Bechhoefer-1/13/2019
50660FGEN DMD paper:m.hmg.oxfordjournals.orgPretty strong preclinical data, and intrituck11/12/2019
50659 DMD Just saw a report that says that FEV1 is primary endpoint, but with lots oftuck-1/12/2019
50658So I double checked with their January 2019 corporate presentation, which is thetuck-1/12/2019
50657Wrt to the NDA, an expiration beyond what is available allows for possible regultuck-1/12/2019
50656>>no FGEN options with an expiration beyond June Enquiring minds want to Biomaven-1/12/2019
50655Nothing with TDW beyond June 21st. less than 200 total open interest (all strIan@SI-1/11/2019
50654Yes, nothing beyond June 2019.George G-1/11/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News